Company news

Guardant Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

March 24, 2025

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

March 10, 2025

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

March 4, 2025

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

February 26, 2025

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

February 19, 2025

Guardant Health Announces Debt Exchange Transactions

February 6, 2025

Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

January 29, 2025

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

January 29, 2025

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

January 22, 2025

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

January 20, 2025

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

January 15, 2025

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 12, 2025

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

January 6, 2025

Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

December 18, 2024

Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

December 17, 2024

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium

December 8, 2024

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

November 24, 2024

Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

November 5, 2024

Guardant Health Named to TIME’s List of the Best Inventions of 2024

October 29, 2024

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024

October 27, 2024

Roberto A. Mignone Joins Guardant Health Board of Directors

October 23, 2024

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

October 14, 2024

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

September 17, 2024

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

September 12, 2024

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

September 9, 2024

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 26, 2024

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

August 21, 2024

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

August 6, 2024

Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

August 6, 2024

Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

July 31, 2024

Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies

July 31, 2024

Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

July 28, 2024

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

July 23, 2024

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

July 22, 2024

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

July 17, 2024

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

June 3, 2024

Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

June 2, 2024

Guardant Health Named to TIME100 Most Influential Companies

May 30, 2024

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

May 29, 2024

FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

May 22, 2024

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

May 20, 2024

Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week

May 15, 2024

Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

May 8, 2024

Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone

May 6, 2024

FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23

April 21, 2024

Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024

April 17, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

April 2, 2024

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

March 12, 2024

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

February 29, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.